The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data ...

In an interview, Colton Ladbury, MD, discussed new insights from a study and expanded on total marrow irradiation’s potential ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic ...

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms. Prithviraj Bose, MD, professor in ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in ...

Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or ...

Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to ...

Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities ...